• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多学科合作在全球消除 HCV 感染中的关键作用。

Key Role of Multidisciplinary Collaboration towards Global Elimination of HCV Infection.

机构信息

4th Department of Internal Medicine, First Faculty of Medicine, Charles University in Prague, Kateřinská 32, 128 00 Prague 2, Czech Republic.

Remedis, s.r.o., Vladimírova 10, 140 00 Prague 4, Czech Republic.

出版信息

Int J Environ Res Public Health. 2022 Mar 31;19(7):4158. doi: 10.3390/ijerph19074158.

DOI:10.3390/ijerph19074158
PMID:35409839
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8998758/
Abstract

The elimination of HCV (hepatitis C virus) infection is, according to WHO (World Health Organization), of international interest. With new diagnostic tools and treatment possibilities, one major challenge for the elimination is to involve infected patients, especially those from socially excluded subpopulations, into HCV infection-treatment programs. The key question is how to help people who inject drugs (PWID) to engage in HCV infection-treatment programs and improve communication between PWID and hepatologists or other medical professionals involved in the treatment of chronic HCV infection. Furthermore, the medical professionals have to accept the changing spectrum of patients with chronic viral hepatitis. Without close interdisciplinary cooperation, it would be extremely difficult to achieve the WHO goal of global viral hepatitis C elimination. Here, we try to encourage our colleagues as well as addictologists and social workers to play their crucial part in the viral hepatitis C eradication process. It is extremely important for the healthcare providers to be able to communicate with addicted clients, inform PWID about the latest developments in the diagnosis and HCV infection treatment, and get them motivated to engage with specialized treatment programs.

摘要

消除 HCV(丙型肝炎病毒)感染是世卫组织(World Health Organization)关注的国际议题。随着新的诊断工具和治疗方法的出现,消除 HCV 感染的主要挑战之一是让受感染的患者,特别是那些来自社会排斥亚人群的患者,参与 HCV 感染治疗计划。关键问题是如何帮助注射毒品者(PWID)参与 HCV 感染治疗计划,并改善 PWID 与参与慢性 HCV 感染治疗的肝病专家或其他医疗专业人员之间的沟通。此外,医疗专业人员必须接受慢性病毒性肝炎患者群体的变化。如果没有密切的跨学科合作,就很难实现世卫组织消除全球丙型肝炎病毒的目标。在这里,我们试图鼓励我们的同事以及成瘾学家和社会工作者在丙型肝炎 C 消除过程中发挥关键作用。医疗保健提供者能够与成瘾患者进行沟通,向 PWID 告知 HCV 感染诊断和治疗的最新进展,并促使他们参与专门的治疗计划,这一点极其重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792b/8998758/59c524b987d0/ijerph-19-04158-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792b/8998758/52f4af33412c/ijerph-19-04158-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792b/8998758/c089376c9fae/ijerph-19-04158-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792b/8998758/20993562a9f2/ijerph-19-04158-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792b/8998758/196f741fa236/ijerph-19-04158-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792b/8998758/b2f4fc7ad542/ijerph-19-04158-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792b/8998758/59c524b987d0/ijerph-19-04158-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792b/8998758/52f4af33412c/ijerph-19-04158-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792b/8998758/c089376c9fae/ijerph-19-04158-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792b/8998758/20993562a9f2/ijerph-19-04158-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792b/8998758/196f741fa236/ijerph-19-04158-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792b/8998758/b2f4fc7ad542/ijerph-19-04158-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/792b/8998758/59c524b987d0/ijerph-19-04158-g006.jpg

相似文献

1
Key Role of Multidisciplinary Collaboration towards Global Elimination of HCV Infection.多学科合作在全球消除 HCV 感染中的关键作用。
Int J Environ Res Public Health. 2022 Mar 31;19(7):4158. doi: 10.3390/ijerph19074158.
2
Viral hepatitis C pandemic: Challenges and threats to its elimination.丙型病毒性肝炎大流行:消除该疾病的挑战和威胁。
J Viral Hepat. 2021 May;28(5):694-698. doi: 10.1111/jvh.13480. Epub 2021 Feb 24.
3
[Acute searching and early diagnosis of HCV infected persons].[丙型肝炎病毒感染者的急性筛查与早期诊断]
Vnitr Lek. 2021 Winter;67(8):455-458.
4
Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.估算澳大利亚注射吸毒人群中丙型肝炎的共识级联护理:直接作用抗病毒治疗的前后。
Int J Drug Policy. 2020 Sep;83:102837. doi: 10.1016/j.drugpo.2020.102837. Epub 2020 Jul 6.
5
Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.澳大利亚减少注射吸毒人群中丙型肝炎感染的进展:ETHOS Engage 研究。
Clin Infect Dis. 2021 Jul 1;73(1):e69-e78. doi: 10.1093/cid/ciaa571.
6
The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.35 个欧洲国家的民间社会对与世界卫生组织 2030 年消除目标相关的丙型肝炎应对措施的监测。
Harm Reduct J. 2020 Nov 19;17(1):89. doi: 10.1186/s12954-020-00439-3.
7
Can hepatitis C virus infection be eradicated in people who inject drugs?注射毒品的人丙型肝炎病毒感染能被根除吗?
Antiviral Res. 2014 Apr;104:62-72. doi: 10.1016/j.antiviral.2014.01.002. Epub 2014 Jan 24.
8
Obstacles and problems in global elimination of viral hepatitis C.全球消除丙型病毒性肝炎的障碍与问题
Cas Lek Cesk. 2020 Fall;159(6):213-216.
9
Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.丙型肝炎病毒控制在注射毒品者中需要克服护理障碍。
World J Gastroenterol. 2013 Nov 28;19(44):7846-51. doi: 10.3748/wjg.v19.i44.7846.
10
Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.资源有限国家中注射吸毒人群丙型肝炎再感染:系统评价和分析。
Int J Environ Res Public Health. 2020 Jul 9;17(14):4951. doi: 10.3390/ijerph17144951.

引用本文的文献

1
The Role of Direct-Acting Antivirals in Enhancing Quality of Life Among Individuals with Chronic Hepatitis C.直接抗病毒药物在提高慢性丙型肝炎患者生活质量中的作用。
Healthcare (Basel). 2025 Apr 11;13(8):878. doi: 10.3390/healthcare13080878.
2
Epidemiological characteristics and spatiotemporal distribution of hepatitis C in southeast coastal areas of China from 2015 to 2022.2015年至2022年中国东南沿海地区丙型肝炎的流行病学特征及时空分布
BMC Infect Dis. 2025 Mar 21;25(1):394. doi: 10.1186/s12879-025-10778-w.
3
Primary healthcare as a strategy for eliminating hepatitis C: the METRIC toolkit.

本文引用的文献

1
Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis.全球慢性丙型肝炎病毒感染的治疗路径:一项系统评价和荟萃分析。
J Viral Hepat. 2021 Oct;28(10):1340-1354. doi: 10.1111/jvh.13574. Epub 2021 Jul 31.
2
Treatment failure with DAA therapy: Importance of resistance.直接抗病毒药物(DAA)治疗失败:耐药性的重要性
J Hepatol. 2021 Jun;74(6):1472-1482. doi: 10.1016/j.jhep.2021.03.004. Epub 2021 Mar 12.
3
EASL recommendations on treatment of hepatitis C: Final update of the series.EASL 丙型肝炎治疗建议:系列的最终更新。
初级保健作为消除丙型肝炎的策略:METRIC 工具包。
Prim Health Care Res Dev. 2024 Nov 7;25:e61. doi: 10.1017/S1463423624000355.
4
Bio-diagnostic performances of microRNAs set related to DNA damage response pathway among hepatitis C virus-associated hepatocellular carcinoma patients.丙型肝炎病毒相关肝细胞癌患者中与DNA损伤反应途径相关的微小RNA组的生物诊断性能
J Genet Eng Biotechnol. 2023 Aug 17;21(1):85. doi: 10.1186/s43141-023-00537-2.
J Hepatol. 2020 Nov;73(5):1170-1218. doi: 10.1016/j.jhep.2020.08.018. Epub 2020 Sep 15.
4
Viral resistance in HCV infection.丙型肝炎病毒感染的病毒耐药性。
Curr Opin Virol. 2018 Oct;32:115-127. doi: 10.1016/j.coviro.2018.10.005. Epub 2018 Nov 12.
5
Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis.直接作用抗病毒药物治疗丙型肝炎在药物使用者和注射毒品者中的应用:系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2018 Nov;3(11):754-767. doi: 10.1016/S2468-1253(18)30304-2. Epub 2018 Sep 21.
6
Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs.全球、区域和国家层面最近注射吸毒人群丙型肝炎感染的估计。
Addiction. 2019 Jan;114(1):150-166. doi: 10.1111/add.14393. Epub 2018 Aug 28.
7
EASL Recommendations on Treatment of Hepatitis C 2018.2018年欧洲肝脏研究学会丙型肝炎治疗推荐意见
J Hepatol. 2018 Aug;69(2):461-511. doi: 10.1016/j.jhep.2018.03.026. Epub 2018 Apr 9.
8
Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.直接作用抗病毒药物时代丙型肝炎病毒再治疗:美国的预测。
Aliment Pharmacol Ther. 2018 Apr;47(7):1023-1031. doi: 10.1111/apt.14527. Epub 2018 Jan 29.
9
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.在 III 期研究中,用索非布韦/维帕他韦治疗基因型 1-6 HCV 感染患者的耐药性分析。
J Hepatol. 2018 May;68(5):895-903. doi: 10.1016/j.jhep.2017.11.032. Epub 2017 Dec 6.
10
Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.全球注射吸毒流行状况以及注射吸毒者的社会人口学特征和艾滋病毒、乙肝病毒及丙肝病毒流行状况:多阶段系统评价。
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207. doi: 10.1016/S2214-109X(17)30375-3. Epub 2017 Oct 23.